Analysts Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Target Price at $34.20

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $34.20.

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. Wedbush upped their price target on shares of Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Finally, Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, January 4th.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $29.43 on Friday. The firm has a market cap of $1.57 billion, a PE ratio of -15.74 and a beta of 1.07. The stock’s fifty day moving average price is $24.06 and its two-hundred day moving average price is $16.53. Tyra Biosciences has a one year low of $6.42 and a one year high of $31.16.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). Sell-side analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Robert J. More sold 10,000 shares of Tyra Biosciences stock in a transaction on Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the transaction, the director owned 3,823,425 shares in the company, valued at approximately $95,585,625. This trade represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 15.20% of the company’s stock.

Institutional Trading of Tyra Biosciences

Several large investors have recently bought and sold shares of TYRA. Federated Hermes Inc. lifted its holdings in shares of Tyra Biosciences by 586.3% in the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after acquiring an additional 1,841 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares during the last quarter. SG Americas Securities LLC acquired a new position in Tyra Biosciences during the 3rd quarter worth approximately $133,000. Public Employees Retirement System of Ohio bought a new position in Tyra Biosciences in the 2nd quarter valued at approximately $177,000. Finally, Russell Investments Group Ltd. boosted its position in Tyra Biosciences by 27.7% in the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after buying an additional 2,766 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.